• LAST PRICE
    4.6500
  • TODAY'S CHANGE (%)
    Trending Up0.0600 (1.3072%)
  • Bid / Lots
    4.5200/ 1
  • Ask / Lots
    5.2500/ 1
  • Open / Previous Close
    4.7100 / 4.5900
  • Day Range
    Low 4.5000
    High 4.7100
  • 52 Week Range
    Low 2.1163
    High 7.2225
  • Volume
    113,420
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 4.59
TimeVolumeRLMD
09:32 ET5524.5
09:39 ET1004.61
09:41 ET1004.54
09:43 ET1004.64
09:45 ET1004.53
09:59 ET16504.62
10:01 ET10984.58
10:03 ET2004.62
10:08 ET2004.58
10:10 ET1004.57
10:14 ET1074.59
10:17 ET1044.59
10:21 ET7014.6
10:28 ET3034.6
10:33 ET4124.61
10:35 ET1004.625
10:37 ET1104.61
10:42 ET2004.62
10:46 ET2004.63
10:50 ET2004.62
10:51 ET2104.62
11:00 ET4334.62
11:02 ET34474.62
11:04 ET2004.62
11:06 ET1004.62
11:08 ET1004.6
11:09 ET269454.595
11:11 ET8924.605
11:13 ET1004.6
11:18 ET2004.615
11:22 ET1004.63
11:26 ET2004.6
11:27 ET4004.6
11:31 ET1004.6
11:33 ET2004.6
11:36 ET5464.6
11:38 ET1004.57
11:40 ET4284.55
11:42 ET3004.57
11:44 ET2004.55
11:45 ET1004.56
11:49 ET1004.52
11:51 ET1004.545
11:56 ET1004.58
11:58 ET12944.55
12:03 ET4004.59
12:07 ET2004.57
12:09 ET5004.59
12:12 ET1004.585
12:16 ET2004.55
12:20 ET1004.55
12:21 ET7004.57
12:25 ET1004.57
12:27 ET3004.59
12:30 ET7004.59
12:32 ET3584.59
12:34 ET2004.58
12:36 ET32004.618
12:38 ET20314.64
12:39 ET6004.61
12:43 ET5004.59
12:50 ET2004.59
12:56 ET2004.575
12:59 ET1004.56
01:01 ET12004.58
01:03 ET1004.54
01:06 ET1004.55
01:08 ET2004.57
01:10 ET1004.55
01:12 ET3814.5344
01:14 ET3104.5587
01:17 ET1004.53
01:19 ET1004.56
01:21 ET1004.54
01:26 ET2004.54
01:28 ET1004.52
01:30 ET2044.5259
01:32 ET2004.545
01:33 ET1004.51
01:35 ET1004.52
01:37 ET1004.55
01:39 ET1004.53
01:44 ET6294.535
01:46 ET21074.52
01:50 ET3004.52
01:51 ET1004.5
01:53 ET2004.51
01:55 ET40004.56
02:00 ET1004.53
02:02 ET7704.54
02:08 ET4004.56
02:09 ET1004.565
02:13 ET3004.5619
02:20 ET8914.535
02:24 ET8404.54
02:26 ET15004.5427
02:27 ET6004.55
02:29 ET1004.57
02:31 ET2004.54
02:33 ET7984.57
02:36 ET2004.59
02:38 ET3164.59
02:40 ET5004.58
02:42 ET1004.6
02:44 ET1004.58
02:47 ET2004.55
02:49 ET3504.55
02:51 ET1004.56
02:58 ET9004.5714
03:00 ET1004.57
03:07 ET1004.58
03:09 ET1004.57
03:12 ET5004.59
03:16 ET1504.61
03:20 ET2004.62
03:23 ET1004.63
03:27 ET1004.6172
03:30 ET1004.61
03:32 ET3004.59
03:34 ET2004.58
03:36 ET1004.575
03:39 ET14504.58
03:41 ET6004.5902
03:43 ET2394.59
03:45 ET4004.59
03:48 ET2004.6
03:50 ET4194.6
03:52 ET4004.63
03:54 ET3494.63
03:56 ET9004.64
03:57 ET15004.615
03:59 ET18294.65
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRLMD
Relmada Therapeutics Inc
140.3M
-1.4x
---
United StatesCTXR
Citius Pharmaceuticals Inc
142.8M
-3.5x
---
United StatesCRVO
CervoMed Inc
143.8M
-7.2x
---
United StatesVTGN
Vistagen Therapeutics Inc
142.7M
-1.5x
---
United StatesNVCT
Nuvectis Pharma Inc
145.7M
-5.8x
---
United StatesGALT
Galectin Therapeutics Inc
147.8M
-3.1x
---
As of 2024-03-29

Company Information

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.

Contact Information

Headquarters
2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES, FL, United States 33134
Phone
646-876-3459
Fax
---

Executives

Independent Chairman of the Board
Charles Casamento
Chief Executive Officer, Director
Sergio Traversa
Chief Financial Officer
Maged Shenouda
Chief Accounting, Compliance Officer
Charles Ence
Acting Chief Scientific Officer
Paolo Manfredi

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$140.3M
Revenue (TTM)
$0.00
Shares Outstanding
30.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.19
EPS
$-3.28
Book Value
$2.84
P/E Ratio
-1.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.